RAPT Therapeutics — Investor Presentation (January 2025)
25 slides from RAPT Therapeutics's investor presentation, Jan 13, 2025
Slide 1: January 2025 Corporate Presentation
January 2025 Corporate Presentation
Slide 2: Disclaimer
Disclaimer Statements in this Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding our research and clinical development plans; current and future drug candidates; the development of
Slide 3: RAPT is Developing Transformative Therapies for High-Value Inflammatory Diseases
RAPT is Developing Transformative Therapies for High-Value Inflammatory Diseases RPT904 is a half-life extended omalizumab (Xolair®) “bio-better” with potential to transform the treatment of Food Allergy (FA) and Chronic Spontaneous Urticaria (CSU) Potential best-in-class profile with less frequent
Slide 4: RAPT Therapeutics Pipeline
INFLAMMATION PROGRAMS DISCOVERY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 RPT904 Anti-IgE mAb Next Gen. CCR4 antagonist RAPT Therapeutics Pipeline # RAPT has licensed ex-China rights including US, Europe, and Japan; Jemincare retains China, Taiwan, Hong Kong and Macau * Clinical collaboration with Merck *
Slide 5: Potential to Transform the Treatment of Food Allergy and CSU
Potential to Transform the Treatment of Food Allergy and CSU RPT904
Slide 6: Omalizumab is an Emerging Blockbuster in Large and Growing Food Allergy Market
Omalizumab is an Emerging Blockbuster in Large and Growing Food Allergy Market There are ~17M FA patients in the US1 → ~50% have had severe reactions2 → ~3.4M ER visits/year2 Treatment dominated by inconvenient treatments: food avoidance and single allergen desensitization (i.e. OIT) Omalizumab is t
Slide 7: Strong Reception to RPT904's Profile from Prescribers and Payers
Strong Reception to RPT904’s Profile from Prescribers and Payers Despite omalizumab’s early success, payers and prescribers would welcome a longer-acting treatment like RPT904 for increased compliance and convenience* * Based on primary market research n=140 prescribers, Oct 2024 and n=45 payers, No
Slide 8: CSU Offers Additional Commercial Upside
CSU Offers Additional Commercial Upside CSU affects >1M patients in the US1 Antihistamines are first treatment step, but ~400k patients not controlled on antihistamines2 Omalizumab is only approved biologic for CSU after failure of antihistamines RPT904 positioned to be preferred choice in front-lin
Slide 9: A Potential Best-in-Class Omalizumab Bio-Better mAb
A Potential Best-in-Class Omalizumab Bio-Better mAb RPT904
Slide 10: RPT904: Minimally Altered to Optimize Dosing Frequency While Targeting Clinically Validated Epitope
RPT904: Minimally Altered to Optimize Dosing Frequency While Targeting Clinically Validated Epitope Omalizumab as starting point Retains clinically validated epitope YTE mutation: half-life extension Additional conservative improvements Affinity maturation: ~4-fold affinity over omalizumab PTM site
Slide 11: Potential Best-In-Class anti-IgE Option for Food Allergy
Potential Best-In-Class anti-IgE Option for Food Allergy Potential Attributes RPT904 Omalizumab Clinically validated epitope Effective on multiple allergens Convenience of Q8W/Q12W dosing Access to High IgE and/or Weight Patients Simplified Dosing Table
Slide 12: Phase 1 Healthy Volunteer Data and Dose Estimations
Phase 1 Healthy Volunteer Data and Dose Estimations RPT904
Slide 13: Jemincare Phase 1 Healthy Volunteer Study Design
Jemincare Phase 1 Healthy Volunteer Study Design: Double-blind, placebo-controlled single ascending dose study of RPT904 (JYB1904) and an omalizumab comparator in healthy Chinese subjects Objectives: Tolerability, safety, immunogenicity, PK and PD Route of administration: subcutaneous (SC) injection
Slide 14: Jemincare Phase 1 Trial Shows Longer Half-Life and Superior IgE Reduction
Jemincare Phase 1 of RPT904 Trial Shows Longer Half-Life and Superior IgE Reduction Compared to Omalizumab At 150 mg, half life for RPT904 was 60 Days vs. 26 days for omalizumab Superior free IgE reduction relative to omalizumab PD comparisons of absolute free-IgE levels to other trials not possible
Slide 15: Omalizumab FA Dosing Table is Complex and Excludes High IgE/Weight Patients
Omalizumab FA Dosing Table is Complex and Excludes High IgE/Weight Patients Approved food allergy table for omalizumab based on well-established PK/PD models and target free IgE levels 8 dose strengths 75-600 mg; 2 frequencies Q2 or Q4W (13 different regimens) ~30% of FA patients excluded from label
Slide 16: Pharmacodynamic Simulations Support Q12W Dosing In Most Patients
Pharmacodynamic Simulations Support Q12W Dosing In Most Patients Omalizumab 150 mg Q4W is approved dose; achieves target IgE levels Q8W would not achieve target levels RPT904 at 150 mg Q12W predicted to achieve target IgE Levels Perform simulations at 150, 300 and 600 mg Q12W across table *Target fr
Slide 17: Phase 2 Trial Designs
Phase 2 Trial Designs RPT904
Slide 18: Proposed Phase 2b Randomized Double-Blind Placebo-Controlled Study in Food Allergy
RPT904 Q12W regimen (N=30) Primary Endpoint: Prespecified threshold by oral food challenge N=75 (2:2:1 Q12W, Q8W regimens and placebo) US/European clinical sites ~18 months from FPI to topline data Proposed Phase 2b Randomized Double-Blind Placebo-Controlled Study of RPT904 Monotherapy in Food Aller
Slide 19: Phase 2b FA Simplified Dosing Regimens Cover Entire Omalizumab Dosing Table
Phase 2b FA Simplified Dosing Regimens Cover Entire Omalizumab Dosing Table Randomization Illustrative simplified dosing table based on baseline IgE and weight 3 dose strengths compared to omalizumab’s 8 dose strengths Plan is to include patients currently excluded from omalizumab label Additional P
Slide 20: Jemincare Asthma and CSU Clinical Development Plan
Jemincare Asthma and CSU Clinical Development Plan 2025 2026 2027 2028 2029 2030 Phase 2a Asthma Data Phase 2 CSU Data Phase III Asthma Start Phase III Asthma Data Phase III CSU Start Phase III CSU Data Phase 2a Asthma Patients with mod-severe asthma (N=60) 3 dose levels of JYB1904 Q8W vs. omalizuma
Slide 21: RPT904 Anticipated Milestones
RPT904 Anticipated Milestones 1H 2025 2H 2025 1H 2026 2H 2026 1H 2027 2H 2027 FA Phase 2b Start (US/Europe) FA Phase 2b Data CSU Phase 2 or 3 Start (US/Europe) Asthma Data (China) CSU Data (China) PK/PD HV Data PK/PD Atopic Data Jemincare RAPT
Slide 22: Next Generation CCR4 Antagonist
First-in-Class Oral Th2 Inhibitor for Inflammatory Diseases Next Generation CCR4 Antagonist
Slide 23: First-in-Class Oral Th2 Inhibitor for Inflammatory Diseases
First-in-Class Oral Th2 Inhibitor for Inflammatory Diseases Highly potent and selective once-daily oral CCR4 antagonist designed to safely reduce Th2-inflammation Next generation CCR4 antagonist with improved potency and liver safety margins Data from zelnecirnon Phase 2 trials in asthma and atopic
Slide 24: RAPT is Developing Transformative Therapies for High-Value Inflammatory Diseases
RAPT is Developing Transformative Therapies for High-Value Inflammatory Diseases RPT904 is a half-life extended omalizumab (Xolair®) “bio-better” with potential to transform the treatment of Food Allergy (FA) and Chronic Spontaneous Urticaria (CSU) Potential best-in-class profile with less frequent
Slide 25: Thank You
Thank You
RAPT Therapeutics — Investor Presentation (January 2025) on 6ix